Titan Pharmaceuticals (TTNP) Competitors $4.24 -0.06 (-1.40%) Closing price 09/12/2025 03:55 PM EasternExtended Trading$4.16 -0.09 (-2.00%) As of 09/12/2025 07:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TTNP vs. SNYR, LIXT, QTTB, AYTU, NAII, FNCH, ASBP, CING, CTXR, and LEXXShould you be buying Titan Pharmaceuticals stock or one of its competitors? The main competitors of Titan Pharmaceuticals include Synergy CHC (SNYR), Lixte Biotechnology (LIXT), Q32 Bio (QTTB), Aytu BioPharma (AYTU), Natural Alternatives International (NAII), Finch Therapeutics Group (FNCH), Aspire Biopharma (ASBP), Cingulate (CING), Citius Pharmaceuticals (CTXR), and Lexaria Bioscience (LEXX). These companies are all part of the "pharmaceutical products" industry. Titan Pharmaceuticals vs. Its Competitors Synergy CHC Lixte Biotechnology Q32 Bio Aytu BioPharma Natural Alternatives International Finch Therapeutics Group Aspire Biopharma Cingulate Citius Pharmaceuticals Lexaria Bioscience Titan Pharmaceuticals (NASDAQ:TTNP) and Synergy CHC (NASDAQ:SNYR) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, analyst recommendations, valuation, profitability, risk, institutional ownership and media sentiment. Do analysts recommend TTNP or SNYR? Synergy CHC has a consensus target price of $10.00, suggesting a potential upside of 362.96%. Given Synergy CHC's stronger consensus rating and higher probable upside, analysts plainly believe Synergy CHC is more favorable than Titan Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Titan Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Synergy CHC 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 Which has preferable earnings & valuation, TTNP or SNYR? Synergy CHC has higher revenue and earnings than Titan Pharmaceuticals. Titan Pharmaceuticals is trading at a lower price-to-earnings ratio than Synergy CHC, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTitan PharmaceuticalsN/AN/A-$4.71M-$2.95-1.44Synergy CHC$34.83M0.59$2.12M$0.385.68 Does the media refer more to TTNP or SNYR? In the previous week, Synergy CHC had 3 more articles in the media than Titan Pharmaceuticals. MarketBeat recorded 6 mentions for Synergy CHC and 3 mentions for Titan Pharmaceuticals. Titan Pharmaceuticals' average media sentiment score of 0.63 beat Synergy CHC's score of 0.32 indicating that Titan Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Titan Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Synergy CHC 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals & insiders hold more shares of TTNP or SNYR? 31.5% of Titan Pharmaceuticals shares are owned by institutional investors. 0.7% of Titan Pharmaceuticals shares are owned by company insiders. Comparatively, 56.6% of Synergy CHC shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Is TTNP or SNYR more profitable? Synergy CHC has a net margin of 10.02% compared to Titan Pharmaceuticals' net margin of 0.00%. Synergy CHC's return on equity of -18.56% beat Titan Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Titan PharmaceuticalsN/A -108.60% -95.64% Synergy CHC 10.02%-18.56%20.28% SummarySynergy CHC beats Titan Pharmaceuticals on 13 of the 15 factors compared between the two stocks. Get Titan Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for TTNP and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TTNP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TTNP vs. The Competition Export to ExcelMetricTitan PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.64M$3.15B$5.78B$10.18BDividend YieldN/A2.32%5.73%4.60%P/E Ratio-1.4421.5775.4626.02Price / SalesN/A254.90464.4091.13Price / CashN/A44.4425.8129.91Price / Book1.599.6112.166.25Net Income-$4.71M-$53.29M$3.29B$270.76M7 Day Performance1.56%0.57%0.73%2.54%1 Month Performance-15.03%4.56%4.41%5.73%1 Year Performance-23.47%10.44%62.61%25.85% Titan Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TTNPTitan Pharmaceuticals0.1422 of 5 stars$4.24-1.4%N/A-23.5%$5.64MN/A-1.4410Short Interest ↑SNYRSynergy CHC3.9659 of 5 stars$2.28-0.4%$10.00+338.6%N/A$21.52M$34.83M6.0040LIXTLixte Biotechnology0.8812 of 5 stars$4.65+7.5%N/A+202.0%$21.41MN/A-3.644Short Interest ↓Gap DownQTTBQ32 Bio2.751 of 5 stars$1.74-0.6%$12.17+599.2%-95.8%$21.23M$1.16M-0.4039Gap UpAYTUAytu BioPharma4.0296 of 5 stars$2.30+1.2%$10.00+335.2%-8.5%$20.79M$81M-3.22160NAIINatural Alternatives International1.6419 of 5 stars$3.32-2.6%N/A-43.6%$20.51M$125.48M-2.39290Positive NewsShort Interest ↓FNCHFinch Therapeutics Group1.4005 of 5 stars$12.70flatN/A+9.7%$20.40MN/A-1.44190Negative NewsShort Interest ↓ASBPAspire BiopharmaN/A$0.41-19.9%N/AN/A$20.31MN/A0.00N/APositive NewsCINGCingulate2.9627 of 5 stars$3.74-0.3%$26.25+601.9%-26.9%$20.23MN/A-0.9120Positive NewsCTXRCitius Pharmaceuticals2.5046 of 5 stars$1.18-3.7%$53.00+4,410.6%-90.7%$19.99MN/A0.0020News CoverageAnalyst UpgradeShort Interest ↑LEXXLexaria Bioscience3.8788 of 5 stars$1.01-2.8%$4.00+295.6%-65.3%$19.78M$460K-1.517Negative NewsShort Interest ↓ Related Companies and Tools Related Companies Synergy CHC Alternatives Lixte Biotechnology Alternatives Q32 Bio Alternatives Aytu BioPharma Alternatives Natural Alternatives International Alternatives Finch Therapeutics Group Alternatives Aspire Biopharma Alternatives Cingulate Alternatives Citius Pharmaceuticals Alternatives Lexaria Bioscience Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TTNP) was last updated on 9/15/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Titan Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Titan Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TTNP Stock Alerts